Last reviewed · How we verify

NCT03683537

Association Between Changes of GFAP After Surgery and Postoperative Delayed Cognitive Recovery

Completed Last updated 9 May 2025
What this trial tests

trial testing Glial fibrillary acidic protein in Astrogliosis in 30 participants. Completed in 15 December 2021.

Timeline
15 February 2018
Primary endpoint
15 November 2021
15 December 2021

Quick facts

Lead sponsorMoscow Clinical Scientific Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date15 February 2018
Primary completion15 November 2021
Estimated completion15 December 2021
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Moscow Clinical Scientific Center

Who can join

60 and older, any sex, with Astrogliosis or Postoperative Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of serum level of glial fibrillary acidic protein (GFAP) before surgery (on the day of surgery), 24 hours after surgery and on 3 or 4 postoperative day. Neuropsychological testing before surgery and on 3 or 4 day after surgery. Investigation of relationship between changes of GFAP and scores of neuropsychological tests.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Moscow Clinical Scientific Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03683537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing